Anatomic Pathology Market Outlook 2031
The global anatomic pathology market size was valued at USD 37.56 billion in 2022 and is projected to reach USD 69.05 Billion by 2031 expand at a substantial CAGR 7% during the forecast period, 2023 – 2031. The growth of the market is attributed to the rising dependence on biomarkers that are based on pathology procedures and tests to discover tumorigenesis and malignancy. The growth in the use of clinical biomarkers allows pathologists to find out disease pathogenesis at a molecular level and helps for better patient outcomes by clinical decision-making.
The anatomic pathological practices are improved by using advanced equipment such as gross imaging, digital microscopes, and staining systems. Unlike other conventional techniques, these digital imaging devices help to provide better solutions such as specific and accurate result. The use of digital imaging is a key factor expected to fuel the anatomic pathology market. Several companies in the market are constantly engaged in efforts to introduce upgraded and advanced pathology development to offer ease of use and favorable design.
Furthermore, key companies are making agreement and partnership for effective portfolio to avoid challenges which affects disease management. For instance, Sakura Finetek USA, in October 2018, partnered with Henry Ford Health System Pathology and Laboratory Medicine for the advancement of automation level in anatomic pathology laboratories. The integration of automation optimizes anatomical pathology with higher productivity by reducing turnaround time and errors in labs.
Anatomic Pathology Market Trends, Drivers, Restraints, and Opportunities
Growing number of pathology training programs being conducted by governments on regular intervals with an aim to spread awareness about technological advancement and legal issues of anatomic pathology. This is expected to boost the market.
Rising prevalence and incidences of chronic illness such as cancer, diabetes, and cardiovascular diseases globally are key factors responsible to drive the market growth.
Growing number of the world population, rising demand for pathology services, and growing elderly population are some factors driving the market.
Lack of high skilled laboratories staffs and technicians handling the processing number of specimens and other diagnostic procedures are expected to restrict the anatomic pathology market growth.
Ongoing vast R&D activities to develop innovative technology and new devices for anatomic pathology researches are offering lucrative opportunities for the market growth.
Scope of the Anatomic Pathology Market Report
The report on the global anatomic pathology market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Anatomic Pathology Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products & Services (Instruments [Microtomes & Cryostat, Tissue Processors, Automatic Stainers, and Other Products], Consumables [Reagents & Antibodies, Probes & Kits, and Others], and Services), Applications (Disease Diagnosis, Drug Discovery & Development, and Others), End-Users (Hospitals, Research Laboratories, Diagnostic Laboratories, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Thermo Fisher Scientific, Inc., Cardinal Health, Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Sakura Finetek USA, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Inc., BioGenex, and Bio SB
Anatomic Pathology Market Segment Insights
Consumables segment to hold a large market share
On the basis of products and services, the global anatomic pathology market is divided into instruments, consumables, and services. The products & services segment is further divided into instruments, consumables, and services. The instruments segment is sub-divided into microtomes & cryostat, tissue processors, automatic stainers, and other products. The consumables segment consists of reagents & antibodies, probes & kits, and others.
The consumables segment is projected to hold a large market share during the forecast period owing to accessibility of wide-ranging consumable products for anatomic pathology and ongoing advanced technological development. However, the instruments segment is anticipated to expand at a significant CAGR due to the presence of many market participants available with improved design of instruments.
Sakura Finetek launched manual microtome Accu-Cut SRM 300 LT in September 2018. This product was integrated with a new feature called 4-color LED-backlit 3D Precision Chuck. For quick visualization of translucent biopsies, this feature allows to observe paraffin-embedded tissue samples in simplified way.
Drug Discovery & Development segment is expected to grow at a rapid pace
Based on applications, the global anatomic pathology market is divided into disease diagnosis, drug discovery & development, and others. The disease diagnosis segment is projected to constitute a large market share in the coming years owing to wide research on anatomic pathology protocols that gives an opportunity to discover disease etiology and associated outcomes.
Hence, in 2019, the segment held a major revenue market share due to extensive applications in disease. The disease diagnosis process at inflammatory and proliferating stromal cells stage aims on detection of tumor, therefore, it reduces costs related to tumor eradication. Additionally, manufacturers are emphasizing on innovation and novel diagnostics techniques, which can fuel the segment growth.
The drug discovery & development segment is projected to expand at a rapid pace over the forecast period owing to wide adoption of the technique for drug discovery and development. During preclinical trials, tissue analysis are extensively adopted by pathologists, which provide plenty of information for pharmaceutical manufacturers. In toxicology assessment, anatomic pathology plays important role in evaluating advance effects of candidate drugs.
Hospital segment to account for a key share
Based on end-users, the global anatomic pathology market is divided into hospitals, research laboratories, diagnostic laboratories, and others. In 2019 the hospitals segment dominated the market in terms of revenue generation due to growing rate of hospitalization of cancer patients along with frequent readmissions in hospitals.
The segment is expected to hold a key market share in the coming years owing to high development of hospital based pathological laboratories and availability of well-trained staff and well-developed healthcare infrastructure. The diagnostic laboratories segment is projected to constitute a large market share in the coming years owing to wide development in advanced testing and equipment.
Moreover, the rapid establishment of several research organizations based on diagnostic laboratories and growing number of clinical trials through different ongoing projects are expected to boost the segment growth. To achieve high degree of patient satisfaction, research laboratories are providing complete information about functioning of diseased tissues.
North America to constitute a considerable share
On the basis of regions, the global anatomic pathology market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large market share in 2019 and is expected to constitute a considerable share in the coming years due to governments’ initiatives to encourage extensive research in the field. The presence of major players and increasing implementation of tissue procedures related to diagnosis in disease screening are key drivers for the regional market growth.
Moreover, availability of favorable reimbursement policies especially in the US plays a crucial role to help the regional market growth. On the other hand, the market in Asia Pacific is projected to exhibit a high CAGR during the forecast period due to strengthening demand for franchising pathology laboratories, advanced imaging modalities and rising in facilities of better patient care in the region.
The global anatomic pathology market has been segmented on the basis of
Products and Services
- Microtomes & Cryostat
- Tissue Processors
- Automatic Stainers
- Other Products
- Reagents & Antibodies
- Probes & Kits
- Disease Diagnosis
- Drug Discovery & Development
- Research Laboratories
- Diagnostic Laboratories
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Thermo Fisher Scientific, Inc.
- Cardinal Health, Inc.
- F. Hoffmann-La Roche AG
- Agilent Technologies, Inc.
- Sakura Finetek USA, Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories, Inc.
- Bio SB.A
Key companies competing in anatomic pathology market are Thermo Fisher Scientific, Inc., Cardinal Health, Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Sakura Finetek USA, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Inc., BioGenex, and Bio SB.
These players were implementing many different strategies to enhance their share in market during the forecast period. Some of the strategies are business expansion, collaborative development and product developments. For instance, for in situ hybridization Agilent Technologies launched a range of probes in June 2018, such as CCND1, BCL6, BCL2, IGH/BCL2, IGH, MALT1, IGH/CCND1, and IGH/MYC.